LABELS · 5a6cd8e9-9d15-d428-e063-6294a90a4dfb

Tudriqev

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date: 2026-09-01
Captured: 2026-09-09T23:37:47.659725+00:00
Current indication reconciliation: Not reconciled

Indications and usage: exact source text

1 INDICATIONS AND USAGE TUDRIQEV™ is indicated in combination with nivolumab for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression with a programmed death receptor-1 (PD-1)-blocking antibody-based regimen. This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response [ see Clinical Studies (14) ]. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s). TUDRIQEV is a genetically modified oncolytic viral therapy indicated in combination with nivolumab for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression with a programmed death receptor-1 (PD-1)-blocking antibody-based regimen. This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s). ( 1 )

Full extracted label fields

application numbers

BLA125827

boxed warning exact

brand names

Tudriqev

current indication status

not_reconciled

dailymed set url

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=26627b8d-91ac-4f76-a213-7e25efd024d1

generic names

VUSOLIMOGENE ODERPAREPVEC-WTPG

5a6cd8e9-9d15-d428-e063-6294a90a4dfb

indications and usage exact

1 INDICATIONS AND USAGE TUDRIQEV™ is indicated in combination with nivolumab for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression with a programmed death receptor-1 (PD-1)-blocking antibody-based regimen. This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response [ see Clinical Studies (14) ]. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s). TUDRIQEV is a genetically modified oncolytic viral therapy indicated in combination with nivolumab for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression with a programmed death receptor-1 (PD-1)-blocking antibody-based regimen. This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s). ( 1 )

indications and usage tables exact

is original packager

true

manufacturer names

Replimune, Inc.

matched search terms

melanoma

package ndcs

83616-106-01
83616-106-11
83616-107-01
83616-107-11

product ndcs

83616-106
83616-107

product types

HUMAN PRESCRIPTION DRUG

recent major changes exact

record type

complete_spl_indications_section_candidate

routes

INTRATUMOR

rxcuis

source batch

file

/private/tmp/cancer-full-research/indications/raw/labels-00300.json

Source passages and status connections

Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

Passage 1 · positive indication candidate

application numbers

BLA125827

brand names

Tudriqev

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 469
end exclusive: true
exact text: 1 INDICATIONS AND USAGE TUDRIQEV™ is indicated in combination with nivolumab for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression with a programmed death receptor-1 (PD-1)-blocking antibody-based regimen. This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response [ see Clinical Studies (14) ]. Continued approval for this indication may be con
label id: 5a6cd8e9-9d15-d428-e063-6294a90a4dfb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d3b1d8424b56dc4e5e84160baa969163a61c7044830e54818c2d43e2904ece84
start: 0

current approval status

not_reconciled

duplicate text group

dup-e29e98f0d0d1bb003c7a

extraction review status

automated_candidate_pending_source_review

generic names

VUSOLIMOGENE ODERPAREPVEC-WTPG

ind-span-485f03d7230b9323eeb6

label id

5a6cd8e9-9d15-d428-e063-6294a90a4dfb

positive predicate support span

end: 46
end exclusive: true
exact text: is indicated
label id: 5a6cd8e9-9d15-d428-e063-6294a90a4dfb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d3b1d8424b56dc4e5e84160baa969163a61c7044830e54818c2d43e2904ece84
start: 34

qualifier mentions

context exact
ndicated in combination with nivolumab for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienc
kind
age
polarity
not_inferred
span
end
112
end exclusive
true
exact text
adult patients
label id
5a6cd8e9-9d15-d428-e063-6294a90a4dfb
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
d3b1d8424b56dc4e5e84160baa969163a61c7044830e54818c2d43e2904ece84
start
98
context exact
ion with nivolumab for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression with a programmed death recept
kind
stage_or_setting
polarity
not_inferred
span
end
165
end exclusive
true
exact text
unresectable advanced cutaneous melanoma who ex
label id
5a6cd8e9-9d15-d428-e063-6294a90a4dfb
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
d3b1d8424b56dc4e5e84160baa969163a61c7044830e54818c2d43e2904ece84
start
118
context exact
1 INDICATIONS AND USAGE TUDRIQEV™ is indicated in combination with nivolumab for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression with a programmed death receptor-1 (PD-1)-blocking antibody-based regimen.
kind
regimen
polarity
not_inferred
span
end
226
end exclusive
true
exact text
in combination with nivolumab for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression with a programmed death recepto
label id
5a6cd8e9-9d15-d428-e063-6294a90a4dfb
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
d3b1d8424b56dc4e5e84160baa969163a61c7044830e54818c2d43e2904ece84
start
47

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

source span

end: 269
end exclusive: true
exact text: 1 INDICATIONS AND USAGE TUDRIQEV™ is indicated in combination with nivolumab for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression with a programmed death receptor-1 (PD-1)-blocking antibody-based regimen.
label id: 5a6cd8e9-9d15-d428-e063-6294a90a4dfb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d3b1d8424b56dc4e5e84160baa969163a61c7044830e54818c2d43e2904ece84
start: 0

source url

https://api.fda.gov/drug/label.json?search=id%3A%225a6cd8e9-9d15-d428-e063-6294a90a4dfb%22

spl effective date

2026-09-01

spl set id

26627b8d-91ac-4f76-a213-7e25efd024d1

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 2 · approval contingency

application numbers

BLA125827

brand names

Tudriqev

classification reasons

approval_contingency_words

clinical review status

pending

content role

approval_contingency

context span

end: 619
end exclusive: true
exact text: olumab for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression with a programmed death receptor-1 (PD-1)-blocking antibody-based regimen. This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response [ see Clinical Studies (14) ]. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s). TUDRIQEV is a genetically modified oncolytic viral therapy indicated in comb
label id: 5a6cd8e9-9d15-d428-e063-6294a90a4dfb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d3b1d8424b56dc4e5e84160baa969163a61c7044830e54818c2d43e2904ece84
start: 70

current approval status

not_reconciled

duplicate text group

dup-71fc1dee68d20a745b19

extraction review status

automated_candidate_pending_source_review

generic names

VUSOLIMOGENE ODERPAREPVEC-WTPG

ind-span-4ce65b7066ef04cc0a1a

label id

5a6cd8e9-9d15-d428-e063-6294a90a4dfb

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

source span

end: 419
end exclusive: true
exact text: This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response [ see Clinical Studies (14) ].
label id: 5a6cd8e9-9d15-d428-e063-6294a90a4dfb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d3b1d8424b56dc4e5e84160baa969163a61c7044830e54818c2d43e2904ece84
start: 270

source url

https://api.fda.gov/drug/label.json?search=id%3A%225a6cd8e9-9d15-d428-e063-6294a90a4dfb%22

spl effective date

2026-09-01

spl set id

26627b8d-91ac-4f76-a213-7e25efd024d1

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 3 · approval contingency

application numbers

BLA125827

brand names

Tudriqev

classification reasons

approval_contingency_words

clinical review status

pending

content role

approval_contingency

context span

end: 742
end exclusive: true
exact text: eceptor-1 (PD-1)-blocking antibody-based regimen. This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response [ see Clinical Studies (14) ]. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s). TUDRIQEV is a genetically modified oncolytic viral therapy indicated in combination with nivolumab for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienced di
label id: 5a6cd8e9-9d15-d428-e063-6294a90a4dfb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d3b1d8424b56dc4e5e84160baa969163a61c7044830e54818c2d43e2904ece84
start: 220

current approval status

not_reconciled

duplicate text group

dup-e17cf8c19d226f5b0620

extraction review status

automated_candidate_pending_source_review

generic names

VUSOLIMOGENE ODERPAREPVEC-WTPG

ind-span-8e048376e54b816b48b1

label id

5a6cd8e9-9d15-d428-e063-6294a90a4dfb

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

source span

end: 542
end exclusive: true
exact text: Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s).
label id: 5a6cd8e9-9d15-d428-e063-6294a90a4dfb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d3b1d8424b56dc4e5e84160baa969163a61c7044830e54818c2d43e2904ece84
start: 420

source url

https://api.fda.gov/drug/label.json?search=id%3A%225a6cd8e9-9d15-d428-e063-6294a90a4dfb%22

spl effective date

2026-09-01

spl set id

26627b8d-91ac-4f76-a213-7e25efd024d1

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 4 · positive indication candidate

application numbers

BLA125827

brand names

Tudriqev

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1034
end exclusive: true
exact text: response rate (ORR) and duration of response [ see Clinical Studies (14) ]. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s). TUDRIQEV is a genetically modified oncolytic viral therapy indicated in combination with nivolumab for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression with a programmed death receptor-1 (PD-1)-blocking antibody-based regimen. This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response. Continued approval for this indication may be contingent upon verification of c
label id: 5a6cd8e9-9d15-d428-e063-6294a90a4dfb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d3b1d8424b56dc4e5e84160baa969163a61c7044830e54818c2d43e2904ece84
start: 343

current approval status

not_reconciled

duplicate text group

dup-d188c77c905cb2d6f735

extraction review status

automated_candidate_pending_source_review

generic names

VUSOLIMOGENE ODERPAREPVEC-WTPG

ind-span-751c57cf9912e6be0555

label id

5a6cd8e9-9d15-d428-e063-6294a90a4dfb

positive predicate support span

end: 611
end exclusive: true
exact text: is a genetically modified oncolytic viral therapy indicated
label id: 5a6cd8e9-9d15-d428-e063-6294a90a4dfb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d3b1d8424b56dc4e5e84160baa969163a61c7044830e54818c2d43e2904ece84
start: 552

qualifier mentions

context exact
ndicated in combination with nivolumab for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienc
kind
age
polarity
not_inferred
span
end
677
end exclusive
true
exact text
adult patients
label id
5a6cd8e9-9d15-d428-e063-6294a90a4dfb
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
d3b1d8424b56dc4e5e84160baa969163a61c7044830e54818c2d43e2904ece84
start
663
context exact
ion with nivolumab for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression with a programmed death recept
kind
stage_or_setting
polarity
not_inferred
span
end
730
end exclusive
true
exact text
unresectable advanced cutaneous melanoma who ex
label id
5a6cd8e9-9d15-d428-e063-6294a90a4dfb
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
d3b1d8424b56dc4e5e84160baa969163a61c7044830e54818c2d43e2904ece84
start
683
context exact
is a genetically modified oncolytic viral therapy indicated in combination with nivolumab for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression with a programmed death receptor-1 (PD-1)-blocking antibody-based regimen.
kind
regimen
polarity
not_inferred
span
end
791
end exclusive
true
exact text
in combination with nivolumab for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression with a programmed death recepto
label id
5a6cd8e9-9d15-d428-e063-6294a90a4dfb
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
d3b1d8424b56dc4e5e84160baa969163a61c7044830e54818c2d43e2904ece84
start
612

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

source span

end: 834
end exclusive: true
exact text: TUDRIQEV is a genetically modified oncolytic viral therapy indicated in combination with nivolumab for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression with a programmed death receptor-1 (PD-1)-blocking antibody-based regimen.
label id: 5a6cd8e9-9d15-d428-e063-6294a90a4dfb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d3b1d8424b56dc4e5e84160baa969163a61c7044830e54818c2d43e2904ece84
start: 543

source url

https://api.fda.gov/drug/label.json?search=id%3A%225a6cd8e9-9d15-d428-e063-6294a90a4dfb%22

spl effective date

2026-09-01

spl set id

26627b8d-91ac-4f76-a213-7e25efd024d1

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 5 · approval contingency

application numbers

BLA125827

brand names

Tudriqev

classification reasons

approval_contingency_words

clinical review status

pending

content role

approval_contingency

context span

end: 1083
end exclusive: true
exact text: olumab for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression with a programmed death receptor-1 (PD-1)-blocking antibody-based regimen. This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s). ( 1 )
label id: 5a6cd8e9-9d15-d428-e063-6294a90a4dfb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d3b1d8424b56dc4e5e84160baa969163a61c7044830e54818c2d43e2904ece84
start: 635

current approval status

not_reconciled

duplicate text group

dup-d937099963780969ed53

extraction review status

automated_candidate_pending_source_review

generic names

VUSOLIMOGENE ODERPAREPVEC-WTPG

ind-span-e8975624585186e66055

label id

5a6cd8e9-9d15-d428-e063-6294a90a4dfb

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

source span

end: 954
end exclusive: true
exact text: This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response.
label id: 5a6cd8e9-9d15-d428-e063-6294a90a4dfb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d3b1d8424b56dc4e5e84160baa969163a61c7044830e54818c2d43e2904ece84
start: 835

source url

https://api.fda.gov/drug/label.json?search=id%3A%225a6cd8e9-9d15-d428-e063-6294a90a4dfb%22

spl effective date

2026-09-01

spl set id

26627b8d-91ac-4f76-a213-7e25efd024d1

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 6 · approval contingency

application numbers

BLA125827

brand names

Tudriqev

classification reasons

approval_contingency_words

clinical review status

pending

content role

approval_contingency

context span

end: 1083
end exclusive: true
exact text: sion with a programmed death receptor-1 (PD-1)-blocking antibody-based regimen. This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s). ( 1 )
label id: 5a6cd8e9-9d15-d428-e063-6294a90a4dfb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d3b1d8424b56dc4e5e84160baa969163a61c7044830e54818c2d43e2904ece84
start: 755

current approval status

not_reconciled

duplicate text group

dup-e17cf8c19d226f5b0620

extraction review status

automated_candidate_pending_source_review

generic names

VUSOLIMOGENE ODERPAREPVEC-WTPG

ind-span-12ee351b570d374ea0ef

label id

5a6cd8e9-9d15-d428-e063-6294a90a4dfb

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

source span

end: 1077
end exclusive: true
exact text: Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s).
label id: 5a6cd8e9-9d15-d428-e063-6294a90a4dfb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d3b1d8424b56dc4e5e84160baa969163a61c7044830e54818c2d43e2904ece84
start: 955

source url

https://api.fda.gov/drug/label.json?search=id%3A%225a6cd8e9-9d15-d428-e063-6294a90a4dfb%22

spl effective date

2026-09-01

spl set id

26627b8d-91ac-4f76-a213-7e25efd024d1

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 7 · unclassified context

application numbers

BLA125827

brand names

Tudriqev

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1083
end exclusive: true
exact text: ed approval based on objective response rate (ORR) and duration of response. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s). ( 1 )
label id: 5a6cd8e9-9d15-d428-e063-6294a90a4dfb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d3b1d8424b56dc4e5e84160baa969163a61c7044830e54818c2d43e2904ece84
start: 878

current approval status

not_reconciled

duplicate text group

dup-7f18f1655d2fcd48ec94

extraction review status

automated_candidate_pending_source_review

generic names

VUSOLIMOGENE ODERPAREPVEC-WTPG

ind-span-065e34ad6248d225617f

label id

5a6cd8e9-9d15-d428-e063-6294a90a4dfb

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

source span

end: 1083
end exclusive: true
exact text: ( 1 )
label id: 5a6cd8e9-9d15-d428-e063-6294a90a4dfb
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: d3b1d8424b56dc4e5e84160baa969163a61c7044830e54818c2d43e2904ece84
start: 1078

source url

https://api.fda.gov/drug/label.json?search=id%3A%225a6cd8e9-9d15-d428-e063-6294a90a4dfb%22

spl effective date

2026-09-01

spl set id

26627b8d-91ac-4f76-a213-7e25efd024d1

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Preserved source evidence · Not medical advice